Nothing Special   »   [go: up one dir, main page]

AR046901A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR046901A1
AR046901A1 ARP040104696A ARP040104696A AR046901A1 AR 046901 A1 AR046901 A1 AR 046901A1 AR P040104696 A ARP040104696 A AR P040104696A AR P040104696 A ARP040104696 A AR P040104696A AR 046901 A1 AR046901 A1 AR 046901A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
compound represented
chemical formula
vehicle
pharmaceutical compositions
Prior art date
Application number
ARP040104696A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR046901A1 publication Critical patent/AR046901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones novedosas útiles para el tratamiento de enfermedades dependientes de los andrógenos. Reivindicación 1: Una composición aceptable desde el punto de vista farmacéutico que comprende una cantidad efectiva del compuesto representado por la fórmula química estructural (1), la cual comprende: o una sal del mismo aceptable desde el punto de vista farmacéutico, mezclado con un vehículo hidrofílico seleccionado entre el grupo que consiste de sílica y celulosa microcristalina, donde dicho compuesto representado por la fórmula química estructural (1) está absorbido sobre dicho vehículo hidrofílico.
ARP040104696A 2003-12-17 2004-12-16 Composiciones farmaceuticas AR046901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53046603P 2003-12-17 2003-12-17

Publications (1)

Publication Number Publication Date
AR046901A1 true AR046901A1 (es) 2005-12-28

Family

ID=34700140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104696A AR046901A1 (es) 2003-12-17 2004-12-16 Composiciones farmaceuticas

Country Status (5)

Country Link
US (2) US20050153976A1 (es)
AR (1) AR046901A1 (es)
PE (1) PE20050759A1 (es)
TW (1) TW200528110A (es)
WO (1) WO2005058281A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CN103442703B (zh) * 2011-05-16 2016-01-27 欧米尼艾克蒂夫健康技术有限公司 具有增强的生物利用度的含姜黄素的水溶性组合物及其方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598113A (en) * 1979-01-17 1980-07-25 Eisai Co Ltd Medicinal powder having improved absorbability
DE3409063A1 (de) * 1984-03-13 1985-09-19 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von fliessfaehigen cholinchlorid-kieselsaeure-pulvern
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US6303167B1 (en) * 1998-11-09 2001-10-16 Archer-Daniels-Midland Company Method of producing vitamin powders
ATE350375T1 (de) * 2001-09-06 2007-01-15 Schering Corp 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2004073689A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material

Also Published As

Publication number Publication date
WO2005058281A1 (en) 2005-06-30
US20050153976A1 (en) 2005-07-14
TW200528110A (en) 2005-09-01
PE20050759A1 (es) 2005-10-26
US20090111831A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
PA8591701A1 (es) Derivados de pirrolopirimidina
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
AR040021A1 (es) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
AR030947A1 (es) Guanidinas de acido cinamico substituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico asi como un medicamento que las contiene
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR046901A1 (es) Composiciones farmaceuticas
DE602004001969D1 (de) Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung
SE0102057D0 (sv) New Salts I
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
AR033779A1 (es) Compuestos utiles en la enfermedad de reflujo

Legal Events

Date Code Title Description
FB Suspension of granting procedure